NewGenIvf Group Limited is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. It specializes in in-vitro fertilization (IVF) treatment and surrogacy and ancillary caring services. Its fertility treatments, such as IVF, intracytoplasmic sperm injection, intrauterine insemination, egg freezing, embryo transfer, gender selection, semen analysis, hysteroscopy, fertility checkups, testicular sperm aspiration and percutaneous epididymal sperm aspiration. Its clinics are in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. It has acquired cytometry technology and assets including 18 fully constructed cell-sorting and dispensing systems, eight partially constructed units and six patents related to advanced microfluidic systems.
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 4.73Mに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 4.73Mです。
黒字転換
同社は黒字転換を果たし、最新の年間純利益はUSD です。
適正水準
同社の最新のPEは0.00で、過去3年間の水準と比較して適正圏にあります。
機関投資家の買い増し
最新の機関投資家の保有株数は2.51K株で、前四半期比で45.71%増加しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は2.55です。